The RAF/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, proliferation and survival. The BRAF gene, one of the human isoforms of RAF, is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. This study was performed to elucidate a possible function of BRAF in squamous cell carcinoma of the head and neck (HNSCC). Mutations of BRAF and KRAS2 were evaluated in 89 HNSCC and corresponding normal mucosa by direct DNA sequencing analyses after microdissection. The results obtained were correlated with histopathological variables. Activating BRAF missense mutations were identified in 3/89 HNSCC (3%). KRAS2 mutations were found in five out of 89 (6%) HNSCC examined. There were no mutations of KRAS2 and BRAF in non-neoplastic mucosa. We failed to observe a correlation between BRAF or KRAS2 mutations and histopathological factors. Our data indicate that BRAF gene mutations are relatively rare events in HNSCC. Although uncommon, BRAF mutations may identify a subset of patients with HNSCC sensitive to targeted therapy.
Since the discovery of the role of RAS oncogenes in tumorigenesis, we have witnessed an explosion of research in the signal transduction area (Hagemann and Rapp, 1999; Fitzgerald et al., 2000) . A key RAS effector pathway involves the kinase cascade RAF/MEK/ERK (MEK: MAP/ERK kinase; ERK: extracellular signal related kinase). In the quest to understand how RAS transmits extracellular growth signals, the MAP kinase (MAPK) pathway has emerged as an important route between membrane-bound RAS and the nucleus Hakimi et al., 2002 , Leder et al., 2002 Gire and Wynford-Thomas, 2000) .
Signalling through the MAPK cascade is transduced by GTP loading of RAS leading to the activation of RAF kinase. In mammalian cells, there are three isoforms of RAF: A-RAF, B-RAF and C-RAF (Mikula et al., 2001; Liao et al., 2001) . Although all three of the RAF isoforms share a common function with respect to MEK phosphorylation, studies have shown that these proteins might be differentially activated by oncogenic RAS (Peyssonnaux and Eychene, 2001) . In contrast to many other tumours of different lineage, oncogenic RAS mutations are rarely found within head and neck squamous cell carcinoma (HNSCC) (Xu et al., 1998; Hao and Rowinsky, 2002; Hoa et al., 2002) . Recently, it was described, that wild-type levels of KRAS2 protein expression is a major determinant of proliferation of HNSCC cells and suggest that amplification of nonmutated KRAS2 in HNSCC contributes to tumour growth (Hoa et al., 2002) .
Recently, mutations of BRAF have been described in about 15% of all human cancers, especially in malignant melanomas . In the present study, we analysed the status of the BRAF gene together with KRAS2 to elucidate a possible role of these genes in the carcinogenesis of HNSCC.
Genomic DNA from HNSCC and corresponding normal epithelium was analysed for BRAF gene mutations. Somatic BRAF mutations were found in 3/89 HNSCC (3%) ( Table 1 ). All mutations were within exons 11 and 15 (Table 1) , with a predominant nucleotide change (Figure 1 ). Two mutations were T1796A (resulting in the substitution of valine 599 by glutamate), a previously documented hot spot. The third mutation was found in exon 11 (G1403T; resulting in the substitution of glycine to alanine at 468). In all three cases the normal epithelium of the same patient exhibits wildtype BRAF. All 89 patients had a wild-type BRAF status in the corresponding normal squamous epithelium.
We failed to detect a significant correlation between the mutation status of BRAF, tumour stage or grade or other histopathological factors (tumour size, vascular invasion, multiplicity, desmoplastic reaction).
Heterozygous mutations of KRAS2 were found in 5/89 HNSCC (6%). Four patients had a mutation of codon 12 and one of codon 13. No patient had multiple mutations (Table 1 ). In the corresponding normal squamous epithelium, KRAS2 was wild type in all cases. We failed to observe an association between KRAS2 mutation pattern and histopathological variables.
We failed to detect a simultaneous BRAF and KRAS2 mutation within the same tumour specimen. However, the number of mutations identified in either gene is too small to evaluate a genetic interaction.
Both KRAS2 and BRAF are members of the RAS-RAF-MEK-ERK-MAP kinase pathway, which mediates cellular response to growth signals (Hakimi et al., 2002) . Whereas was examined in a variety of human malignancies (Garcia et al., 2001) , this is the first study of the mutational status of BRAFand KRAS2 in HNSCC in a large series of patients. In its initial report, Davies et al. (2002) (Rajagopalan et al., 2002) , we detected BRAF mutation only in a small number of HNSCC. Two out of three BRAF mutations occurred at nucleotide 1796, leading to a T to A change at exon 15 of the BRAF gene. It has been shown previously that this mutation in the activation segment, leading to a conversion of valine 599 to glutamic acid, is a hot spot for BRAF mutation in human cancer Yuen et al., 2002; Brase et al., 2002) . As a result of this mutation, a negatively charged residue is inserted adjacent to a regulatory phosphorylation site, mimicking phosphorylation and thus leading to BRAF activation independent of KRAS2 mutation .
Consistent with the proposed autonomous nature of this mutation in the RAS-RAF-MEK-ERK-MAP kinase signalling pathway, mutation of KRAS2 is not required and hence not observed in any of the tumours Figure 1 DNA sequencing was performed on tissue samples of 89 patients with HNSCC after microdissection and DNA extraction as described before (Pindborg et al., 1997; Shanmugaratnam, 1991; . The tumours were located in the oropharynx (33 cases), followed by larynx (25 cases), hypopharynx (18 cases) and floor of mouth (13 cases). According to UICC (2002) , staging of HNSCC was as follows: stage l n ¼ 17, stage ll n ¼ 24, stage lll n ¼ 21 and stage lV n ¼ 27 tumours. All patients were informed of special examination of tumour samples which was in accordance with the ethical standards of the Committee on Human Experimentation of the University of Leipzig. PCR primers were designed to amplify the exon plus at least 50 bp of flanking intronic sequence according to previously published protocols for BRAF sequencing. The primers were adopted from those published in the literature to omit analysing the BRAF pseudogene Yuen et al., 2002; Naoki et al., 2002) . The first exon of KRAS2 was amplified by PCR using primers described recently (Tannapfel et al., 2000; Tannapfel and Weber, 2002) .
carrying V599E, as it was shown previously by Davies et al. (2002) . According to our results, KRAS2 and BRAF mutations never occur simultaneously in HNSCC. Since oncogenic KRAS2 activates wild-type BRAF, but mutated BRAF does not require KRAS2 for growth induction Hakimi et al., 2002) , a simultaneous BRAF and KRAS2 mutation in the same tumour may be redundant. Both KRAS2 and BRAF influence the same effector pathway (promoting cell survival by activating the MAPK pathway); a simultaneous 'double mutation' may not confer a selection advantage for a single tumour cell. To prove this hypothesis, further studies are necessary, especially in preneoplastic lesions or early tumour stages.
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